{
    "root": "23e819c2-693e-476e-929a-822064a0f5f2",
    "code": "34391-3",
    "codeSystem": "2.16.840.1.113883.6.1",
    "displayName": "HUMAN PRESCRIPTION DRUG LABEL",
    "name": "Atorvastatin Calcium",
    "value": "20250520",
    "ingredients": [
        {
            "name": "ATORVASTATIN CALCIUM TRIHYDRATE",
            "code": "48A5M73Z4Q"
        },
        {
            "name": "ANHYDROUS LACTOSE",
            "code": "3SY5LH9PMK"
        },
        {
            "name": "SODIUM CARBONATE",
            "code": "45P3261C7T"
        },
        {
            "name": "SILICON DIOXIDE",
            "code": "ETJ7Z6XBU4"
        },
        {
            "name": "CROSCARMELLOSE SODIUM",
            "code": "M28OL1HH48"
        },
        {
            "name": "HYDROXYPROPYL CELLULOSE, UNSPECIFIED",
            "code": "9XZ8H6N6OH"
        },
        {
            "name": "ARGININE",
            "code": "94ZLA3W45F"
        },
        {
            "name": "MAGNESIUM STEARATE",
            "code": "70097M6I30"
        },
        {
            "name": "MICROCRYSTALLINE CELLULOSE",
            "code": "OP1R32D61U"
        },
        {
            "name": "POLYVINYL ALCOHOL, UNSPECIFIED",
            "code": "532B59J990"
        },
        {
            "name": "TALC",
            "code": "7SEV7J4R1U"
        },
        {
            "name": "TITANIUM DIOXIDE",
            "code": "15FIX9V2JP"
        },
        {
            "name": "POLYETHYLENE GLYCOL, UNSPECIFIED",
            "code": "3WJQ0SDW1A"
        },
        {
            "name": "SOYBEAN LECITHIN",
            "code": "1DI56QDM62"
        },
        {
            "name": "XANTHAN GUM",
            "code": "TTV12P4NEE"
        }
    ],
    "indications": "atorvastatin calcium tablets indicated : •to reduce risk : omyocardial infarction ( myocardial infarction ) , stroke , revascularization procedures , angina adults multiple risk factors coronary heart disease ( chd ) without clinically evident chd omi stroke adults type 2 diabetes mellitus multiple risk factors chd without clinically evident chd onon-fatal myocardial infarction , fatal non-fatal stroke , revascularization procedures , hospitalization congestive heart failure , angina adults clinically evident chd •as adjunct diet reduce low-density lipoprotein cholesterol ( ldl-c ) : oadults primary hyperlipidemia . oadults pediatric patients aged 10 years older heterozygous familial hypercholesterolemia ( hefh ) . •as adjunct ldl-c-lowering therapies , alone treatments unavailable , reduce ldl-c adults pediatric patients aged 10 years older homozygous familial hypercholesterolemia ( hofh ) . •as adjunct diet treatment adults : oprimary dysbetalipoproteinemia ohypertriglyceridemia",
    "contraindications": "• take orally daily without food ( 2.1 ) . • assess ldl-c clinically appropriate , early 4 weeks initiating atorvastatin calcium tablets , adjust necessary ( 2.1 ) . • adults ( 2.2 ) : recommended starting 10 20 mg daily ; range 10 mg 80 mg daily . patients requiring ldl-c reduction > 45 % may start 40 mg daily . • pediatric patients aged 10 years age older hefh : recommended starting 10 mg daily ; range 10 20 mg daily ( 2.3 ) . • pediatric patients aged 10 years age older hofh : recommended starting 10 20 mg daily ; range 10 80 mg daily ( 2.4 ) . • full prescribing information atorvastatin calcium tablet modifications due ( 2.5 ) .",
    "warningsAndPrecautions": "atorvastatin calcium tablets , usp available containing atorvastatin calcium , usp equivalent 10 mg , 20 mg , 40 mg 80 mg atorvastatin . 80 mg tablets white off-white , film-coated , oval , unscored tablets debossed 80on one side tablet blank side . available follows : overbagged 6 film-coated tablets per bag , ndc 55154-4384-6 warning : unit dose package child resistant intended institutional . keep drugs reach children . storage : store 20° 25°c ( 68° 77°f ) . [ usp controlled room temperature . ]",
    "adverseReactions": "•acute liver failure decompensated cirrhosis [ ( 5.3 ) ] •hypersensitivity atorvastatin excipients atorvastatin calcium tablets . hypersensitivity , including anaphylaxis , angioneurotic edema , erythema multiforme , stevens-johnson syndrome , toxic epidermal necrolysis , reported [ ( 6.2 ) ] .",
    "indications_original": "Atorvastatin calcium tablets are indicated:\n                  \n                     \n                        •To reduce the risk of:       \n                           \n                              oMyocardial infarction (MI), stroke, revascularization procedures, and angina in adults with multiple risk factors for coronary heart disease (CHD) but without clinically evident CHD\n                           \n                              oMI and stroke in adults with type 2 diabetes mellitus with multiple risk factors for CHD but without clinically evident CHD\n                           \n                              oNon-fatal MI, fatal and non-fatal stroke, revascularization procedures, hospitalization for congestive heart failure, and angina in adults with clinically evident CHD\n                        \n                     \n                     \n                        •As an adjunct to diet to reduce low-density lipoprotein cholesterol (LDL-C) in:       \n                           \n                              oAdults with primary hyperlipidemia.\n                           \n                              oAdults and pediatric patients aged 10 years and older with heterozygous familial hypercholesterolemia (HeFH).\n                        \n                     \n                     \n                        •As an adjunct to other LDL-C-lowering therapies, or alone if such treatments are unavailable, to reduce LDL-C in adults and pediatric patients aged 10 years and older with homozygous familial hypercholesterolemia (HoFH).\n                     \n                        •As an adjunct to diet for the treatment of adults with:       \n                           \n                              oPrimary dysbetalipoproteinemia\n                           \n                              oHypertriglyceridemia",
    "contraindications_original": "• Take orally once daily with or without food ( 2.1 ). • Assess LDL-C when clinically appropriate, as early as 4 weeks after initiating atorvastatin calcium tablets, and adjust dosage if necessary ( 2.1 ). • Adults ( 2.2 ): o Recommended starting dosage is 10 or 20 mg once daily; dosage range is 10 mg to 80 mg once daily. o Patients requiring LDL-C reduction > 45% may start at 40 mg once daily. • Pediatric Patients Aged 10 Years of Age and Older with HeFH : Recommended starting dosage is 10 mg once daily; dosage range is 10 to 20 mg once daily ( 2.3 ). • Pediatric Patients Aged 10 Years of Age and Older with HoFH : Recommended starting dosage is 10 to 20 mg once daily; dosage range is 10 to 80 mg once daily ( 2.4 ). • See full prescribing information for atorvastatin calcium tablet dosage modifications due to drug interactions ( 2.5 ).",
    "warningsAndPrecautions_original": "Atorvastatin Calcium Tablets, USP are available containing atorvastatin calcium, USP equivalent to 10 mg, 20 mg, 40 mg or 80 mg of atorvastatin.\n                  The 80 mg tablets are white to off-white, film-coated, oval, unscored tablets debossed with     80on one side of the tablet and blank on the other side. They are available as follows:   \n                  Overbagged with 6 film-coated tablets per bag, NDC 55154-4384-6\n                  WARNING: This Unit Dose package is not child resistant and is Intended for Institutional Use Only. Keep this and all drugs out of the reach of children.\n                  \n                     Storage: Store at 20° to 25°C (68° to 77°F). [See USP Controlled Room Temperature.]",
    "adverseReactions_original": "•Acute liver failure or decompensated cirrhosis       [see         Warnings and Precautions (5.3)]       \n                     \n                     \n                        •Hypersensitivity to atorvastatin or any excipients in atorvastatin calcium tablets. Hypersensitivity reactions, including anaphylaxis, angioneurotic edema, erythema multiforme, Stevens-Johnson syndrome, and toxic epidermal necrolysis, have been reported       [see         Adverse Reactions (6.2)]       ."
}